Curanex expands drug pipeline to include cancer cachexia, a multi-billion-dollar market

Curanex Pharmaceuticals Inc

Company adds cancer cachexia as a new core indication beyond its six existing programs (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout).
Global cancer cachexia market was $2.54B in 2024, projected to reach $3.90B by 2033; no approved therapies in US.
Lead program Phyto-N remains in preclinical for ulcerative colitis; Company evaluating further development opportunities in cachexia.
Management sees this as key step in evolving into a broader therapeutics company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.